RxDoctor Payments Data

Mark Moeller, MD

Internal Medicine · Pollocksville, NCNPI 1053304097

Payments from drug & device makers

$789in general payments, 2019–2025

Across 48 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$255
  • Novo Nordisk$112
  • AstraZeneca$111
  • GSK$68
  • Boehringer Ingelheim$42
  • AbbVie$38
  • plus $164 from 9 others

What the payments were for

  • Food & beverage$789100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$789 in reported general payments places this provider in the 70th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$366,007
Medicare patients
426
Services billed
25,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala44$201,061
OzempicSemaglutide104$119,523
EliquisApixaban174$108,631
JardianceEmpagliflozin104$81,663
MounjaroTirzepatide69$69,806
TrulicityDulaglutide34$36,542
FarxigaDapagliflozin Propanediol37$30,041
LinzessLinaclotide27$27,020
XareltoRivaroxaban34$26,585
RybelsusSemaglutide23$21,792
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog36$19,180
EntrestoSacubitril/Valsartan22$16,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,668
Combivent RespimatIpratropium/Albuterol Sulfate23$10,566
Bydureon BciseExenatide Microspheres11$8,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$112$141,315127 claims
PfizerEliquis$11$108,631174 claims
Lilly USA, LLCMounjaro, Trulicity$18$106,347103 claims
Boehringer IngelheimJardiance, Combivent Respimat$42$92,228127 claims
AstraZenecaFarxiga, Nexium$111$37,24450 claims
AbbVieLinzess, Synthroid$38$31,409107 claims
GSKTrelegy Ellipta, Breo Ellipta$68$16,48031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Pollocksville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →